Mette Thomsen, MD; Børge G. Nordestgaard, MD, DMSc
free access
JAMA Intern Med. 2014;174(1):15-22. doi:10.1001/jamainternmed.2013.10522
Thomsen and Nordestgaard test the hypothesis that overweight and obesity with and without metabolic syndrome are associated with increased risk of myocardial infarction and ischemic heart disease. Jackson provides an Invited Commentary.
-
Invited Commentary
Maintaining a Healthy Body Weight Is Paramount
Chandra L. Jackson, PhD, MS; Meir J. Stampfer, MD, DrPH
JAMA Intern Med
Nicholas L. Smith, PhD; Marc Blondon, MD, MS; Kerri L. Wiggins, MS, RD; et al.
free access
JAMA Intern Med. 2014;174(1):25-34. doi:10.1001/jamainternmed.2013.11074
Smith et al compare the relative clinical cardiovascular safety of 2 commonly used oral estrogen drugs鈥攃onjugated equine estrogens and estradiol. Their case-control study compares cardiovascular event risk among 384 postmenopausal women aged 30 to 79 years using oral hormone therapy. Incident venous thrombosis was the primary clinical outcome.
Peter N. Taylor, MSc, MRCP; Ahmed Iqbal, MRCP; Caroline Minassian, MSc; et al.
free access
JAMA Intern Med. 2014;174(1):32-39. doi:10.1001/jamainternmed.2013.11312
To define trends in thyrotropin levels at the initiation of levothyroxine therapy and the risk of developing a suppressed thyrotropin level after treatment, Taylor et al performed a retrospective cohort study using data from the UK Clinical Practice Research Datalink. They assessed the odds of initiation of therapy at thyrotropin levels of 10.0 mIU/L or less.
Ariel Cohen, MD, PhD; Patrick Assyag, MD; Louise Boyer-Chatenet; et al.
free access
JAMA Intern Med. 2014;174(1):40-48. doi:10.1001/jamainternmed.2013.11342
Cohen et al determined whether a nurse-led or dietician-led cardiovascular risk factor education program would improve risk factor reduction over the long term after an acute coronary syndrome. Patients underwent an education program in a House of Education or were treated according to physicians鈥� standard of care. See the Invited Commentary by Fihn.
-
Invited Commentary
Bending the Curve on Cardiovascular Risk
Stephan D. Fihn, MD, MPH
JAMA Intern Med
Martin Than, MBBS; Sally Aldous, MD; Sarah Jane Lord, MBBS; et al.
free access
JAMA Intern Med. 2014;174(1):51-58. doi:10.1001/jamainternmed.2013.11362
Than and coauthors compared the effectiveness of a rapid diagnostic pathway with a standard-care diagnostic pathway for the assessment of patients with possible cardiac chest pain in a usual clinical practice setting. See also the Invited Commentary by Rahko.
Karen E. Joynt, MD, MPH ; Sidney T. Le, BA; E. John Orav, PhD; et al.
free access
JAMA Intern Med. 2014;174(1):61-67. doi:10.1001/jamainternmed.2013.11537
Joynt et al examine CEO compensation at private nonprofit hospitals and examine its relationship with quality metrics. Invited commentary provided by Browner.
-
Invited Commentary
Do Hospitals Really Reward Glitz but Not Quality?
Warren S. Browner, MD, MPH
JAMA Intern Med
Barbara J. Mason, PhD; Susan Quello, BA, BS; Vivian Goodell, MPH; et al.
free access
JAMA Intern Med. 2014;174(1):70-77. doi:10.1001/jamainternmed.2013.11950
Mason and coauthors determine if gabapentin increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner. See the Invited Commentary by Nunes.
Lillian C. Buchhalter; Abigale L. Ottenberg, MA; Tracy L. Webster, RN; et al.
free access
has audio
JAMA Intern Med. 2014;174(1):80-85. doi:10.1001/jamainternmed.2013.11564
Buchhalter and colleagues describe features and outcomes of patients who underwent cardiovascular implantable electronic device deactivation. Also see the Invited Commentary by Matlock and Mandrola.
-
Podcast:
Features and Outcomes of Patients Who Underwent Cardiac Device Deactivation, and Deathbed Shock: Causes and Cures
-
Invited Commentary
The Antidote for Unprepared Patients: A Caring Clinician
Daniel D. Matlock, MD, MPH; John M. Mandrola, MD
JAMA Intern Med
-
Deathbed Shock: Causes and Cures
Katy Butler, BA; Sunita Puri, MD, MS
JAMA Intern Med
Thomas J. Moore, AB; Curt D. Furberg, MD, PhD
free access
JAMA Intern Med. 2014;174(1):90-95. doi:10.1001/jamainternmed.2013.11813
To inform the debate about appropriate standards, Moore and Furberg studied the development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US FDA in 2008. Carpenter provides an Invited Commentary.
Eileen Rillamas-Sun, PhD, MPH; Andrea Z. LaCroix, PhD; Molly E. Waring, PhD; et al.
free access
has audio
JAMA Intern Med. 2014;174(1):98-106. doi:10.1001/jamainternmed.2013.12051
Rillamas-Sun and colleagues investigate whether higher baseline body mass index and waist circumference affect women鈥檚 survival to age 85 years without major chronic disease (coronary disease, stroke, cancer, diabetes mellitus, or hip fracture) and mobility disability.
-
Podcast:
Obesity and Late-Age Survival Without Major Disease or Disability in Older Women
Elsayed Z. Soliman, MD, MSc, MS; Monika M. Safford, MD; Paul Muntner, PhD; et al.
free access
has multimedia
JAMA Intern Med. 2014;174(1):107-114. doi:10.1001/jamainternmed.2013.11912
Soliman and colleagues examine the risk of incident myocardial infarction (MI) associated with atrial fibrillation (AF). In a related editorial, Dukes and Marcus further explore the association between MI and AF.
-
Editorial
Atrial Fibrillation Begets Myocardial Infarction
Jonathan W. Dukes, MD; Gregory M. Marcus, MD, MAS
JAMA Intern Med
Natasha K. Stout, PhD; Larissa Nekhlyudov, MD, MPH; Lingling Li, PhD; et al.
free access
JAMA Intern Med. 2014;174(1):114-121. doi:10.1001/jamainternmed.2013.11958
Stout et al describe breast magnetic resonance imaging trends and indications in a community setting.
Karen J. Wernli, PhD; Wendy B. DeMartini, MD; Laura Ichikawa, MS; et al.
free access
has multimedia
JAMA Intern Med. 2014;174(1):125-132. doi:10.1001/jamainternmed.2013.11963
Wernli et al describe patterns of breast magnetic resonance imaging use in US community practice during the period 2005 through 2009.